APOPTOTIC INHIBITOR OF UNCLEAVABLE CDC6 MUTAION PROTEIN AND APOPTOTIC INDUCER CONTAINING CDC6 DELETED PROTEIN
An apoptosis inhibiting agent is provided to prevent activation of the apoptosis by digesting a Cdc6 protein during the apoptosis process, thereby being usefully used to prevent or treat degenerative diseases induced by abnormal apoptosis such as Alzheimer's disease and Parkinson's disease...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
26.06.2008
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | An apoptosis inhibiting agent is provided to prevent activation of the apoptosis by digesting a Cdc6 protein during the apoptosis process, thereby being usefully used to prevent or treat degenerative diseases induced by abnormal apoptosis such as Alzheimer's disease and Parkinson's disease. An apoptosis inducing agent comprising a p32-tCdc6 protein is provided to show strong apoptosis inducing effect, thereby being usefully used to prevent or treat various cancer diseases induced by abnormal proliferation. An apoptosis inhibiting protein includes 1-290 amino acid sequences of a Cdc6 protein described in SEQ ID : NO. 1 and is characterized in that it includes an amino acid sequence substituted by point mutation of a 290 amino acid and a 442 amino acid. An apoptosis inducing composition includes 1-290 amino acid sequences of a Cdc6 protein described in SEQ ID : NO. 3. An agent for inhibiting apoptosis or treating degenerative diseases comprises the apoptosis inhibiting protein, a gene encoding the protein, or an expression vector including the gene. An agent for inducing apoptosis or treating auto-immune diseases or cancer comprises the apoptosis inducing protein, a gene encoding the protein, or an expression vector including the gene. |
---|---|
Bibliography: | Application Number: KR20060132618 |